Frovatriptan versus zolmitriptan for the acute treatment of migraine: a double-blind, randomized, multicenter, Italian study

[1]  D. Ashcroft,et al.  Meta‐Analysis of the Efficacy and Safety of Zolmitriptan in the Acute Treatment of Migraine , 2007, Headache.

[2]  A. Rapoport.  Acute treatment of headache , 2006, The Journal of Headache and Pain.

[3]  R. Cady,et al.  Sumatriptan: update and review , 2006, Expert opinion on pharmacotherapy.

[4]  E. Balbisi.  Frovatriptan succinate, a 5‐HT1B/1D receptor agonist for migraine , 2004, International journal of clinical practice.

[5]  J. Senard,et al.  Migraine Headache Recurrence: Relationship to Clinical, Pharmacological, and Pharmacokinetic Properties of Triptans , 2003, Headache.

[6]  J. Belsey,et al.  Meta-analysis of oral triptan therapy for migraine: number needed to treat and relative cost to achieve relief within 2 hours. , 2003, Journal of managed care pharmacy : JMCP.

[7]  P J Goadsby,et al.  Triptans (Serotonin, 5-HT1B/1D Agonists) in Migraine: Detailed Results and Methods of A Meta-Analysis of 53 Trials , 2002, Cephalalgia : an international journal of headache.

[8]  A. Dowson,et al.  Review of zolmitriptan and its clinical applications in migraine , 2002, Expert opinion on pharmacotherapy.

[9]  E. Spierings,et al.  Tolerability and Safety of Frovatriptan With Short‐ and Long‐term Use for Treatment of Migraine and in Comparison With Sumatriptan , 2002, Headache.

[10]  C. Dahlöf.  Assessing Patient Preference in Migraine Treatment , 2001, Cephalalgia : an international journal of headache.

[11]  Ferrari,et al.  Guidelines for Controlled Trials of Drugs in Migraine: Second Edition , 2000, Cephalalgia : an international journal of headache.